Literature DB >> 3081778

Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects.

P Vague, I Juhan-Vague, M F Aillaud, C Badier, R Viard, M C Alessi, D Collen.   

Abstract

This study was undertaken to obtain further information on the mechanism by which blood fibrinolytic activity, a balance between plasminogen activators and inhibitors, is lowered in obese subjects. Fasting blood samples were collected from 35 subjects, aged 15 to 45 years, with normal glucose tolerance and a Body Mass Index (BMI) varying widely between 16 and 45 (normal, 19 to 25). Euglobulin Fibrinolytic Activity (EFA) did not correlate with the level of tissue type plasminogen activator (t-PA) related antigen but exhibited a negative correlation with the level of PA inhibitor (r = -.609, P less than 0.01). EFA was negatively and PA inhibitor positively correlated with both BMI (r = -.381, P less than 0.02 and .664, P less than 0.01, respectively) and plasma insulin level (r = .410, P less than 0.02 and .521, P less than 0.01, respectively). Stepwise analysis showed that these correlations were independent. As expected, plasma insulin was correlated with BMI (r = .512, P less than 0.01) and triglyceride level (r = .38, P less than 0.02), total cholesterol with age (r = .379, P less than 0.02). Ten obese subjects were submitted to a 24-hour fast. While body weight did not change appreciably, plasma insulin decreased from 22.3 +/- 2.2 to 16.3 +/- 1.1 microU/ml, EFA increased from 3.6 +/- .8 to 4.9 +/- .67 mm, and PA inhibitor decreased from 4.52 +/- .76 to 3.44 +/- .63 IU/mL. All these differences were significant. T-PA-related antigen did not change.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3081778     DOI: 10.1016/0026-0495(86)90209-x

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  52 in total

Review 1.  Sex-related differences in the insulin resistance syndrome.

Authors:  D B Corry
Journal:  Curr Hypertens Rep       Date:  2001-04       Impact factor: 5.369

2.  Elevated expression of transforming growth factor-beta in adipose tissue from obese mice.

Authors:  F Samad; K Yamamoto; M Pandey; D J Loskutoff
Journal:  Mol Med       Date:  1997-01       Impact factor: 6.354

Review 3.  Coronary heart disease in diabetes mellitus--antecedents and associations.

Authors:  P H Winocour
Journal:  Postgrad Med J       Date:  1991-10       Impact factor: 2.401

Review 4.  Plasminogen activator inhibitor-1 (PAI-1): a key factor linking fibrinolysis and age-related subclinical and clinical conditions.

Authors:  Matteo Cesari; Marco Pahor; Raffaele Antonelli Incalzi
Journal:  Cardiovasc Ther       Date:  2010-07-07       Impact factor: 3.023

5.  Effect of a 12-month exercise intervention on serum biomarkers of angiogenesis in postmenopausal women: a randomized controlled trial.

Authors:  Catherine Duggan; Liren Xiao; Ching-Yun Wang; Anne McTiernan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-02-05       Impact factor: 4.254

Review 6.  The role of endothelium in the pathogenesis of diabetic microangiopathy.

Authors:  M La Selva; E Beltramo; P Passera; M Porta; G M Molinatti
Journal:  Acta Diabetol       Date:  1993       Impact factor: 4.280

7.  Disappearance and formation rates of microaneurysms in early diabetic retinopathy.

Authors:  T Hellstedt; I Immonen
Journal:  Br J Ophthalmol       Date:  1996-02       Impact factor: 4.638

8.  Relationship between plasma plasminogen activator inhibitor-1 activity and VLDL triglyceride concentration, insulin levels and insulin sensitivity: studies in randomly selected normo- and hypertriglyceridaemic men.

Authors:  A Asplund-Carlson; A Hamsten; B Wiman; L A Carlson
Journal:  Diabetologia       Date:  1993-09       Impact factor: 10.122

9.  Association of markers of hemostasis with death in HIV-infected women.

Authors:  Elizabeth Kiefer; Donald R Hoover; Qiuhu Shi; Mark H Kuniholm; Michael Augenbraun; Mardge H Cohen; Elizabeth T Golub; Robert C Kaplan; Chenglong Liu; Marek Nowicki; Phyllis C Tien; Russell P Tracy; Kathryn Anastos
Journal:  J Acquir Immune Defic Syndr       Date:  2014-11-01       Impact factor: 3.731

10.  Plasminogen activator inhibitor: a risk factor for myocardial infarction in diabetic patients.

Authors:  R P Gray; J S Yudkin; D L Patterson
Journal:  Br Heart J       Date:  1993-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.